|
시장보고서
상품코드
2130880
코르티코스테로이드 저해제 시장 규모, 점유율 및 성장 분석 : 약제 유형별, 적응증별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Adrenal Corticosteroid Inhibitors Market Size, Share, and Growth Analysis, By Drug Type, By Indication, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 코르티코스테로이드 저해제 시장 규모는 2024년에 7억 8,200만 달러로 평가되며, 2025년 8억 4,300만 달러에서 2033년까지 15억 3,737만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 7.8%로 성장할 것으로 전망되고 있습니다.
전 세계 코르티코스테로이드 억제제 시장은 주로 글루코코르티코이드의 장기 사용으로 인한 의인성 쿠싱병 발생률 증가에 힘입어 성장하고 있으며, 그 결과 코르티솔 저하제가 필요한 환자층이 확대되고 있습니다. 이러한 수요 증가에 따라 건강보험사 및 의료 제공자들은 승인된 억제제를 도입하고 있습니다. 예를 들어 최근 오실로드로스타트가 각국의 보험 약제 리스트에 추가됨에 따라 처방 건수가 현저히 증가한 점을 들 수 있습니다. 또한 mTOR 길항제를 도입한 병용 요법의 개발로 치료 적응증이 확대되면서 시장 기회가 커지고 있습니다. 또한 바이오시밀러의 개발과 디지털 복약 순응도 지원 툴의 발전으로 시장 침투가 촉진되는 동시에, 의료 시스템의 도입 비용을 효과적으로 절감할 수 있을 것으로 기대됩니다. 인공지능 또한 억제제 발굴을 가속화하고, 연구 효율을 높이며, 생명공학 분야의 협력을 촉진함으로써 중요한 역할을 수행하고 있습니다.
전 세계 코르티코스테로이드 억제제 시장의 성장 동인
전 세계 코르티코스테로이드 억제제 시장의 주요 성장 요인은 자가면역 질환 및 염증성 질환의 유병률 증가이며, 이로 인해 효과적인 치료법에 대한 수요가 크게 증가하고 있습니다. 의료 전문가들이 류마티스 관절염, 루푸스, 천식 등의 질환을 보다 효과적으로 관리하기 위해 노력함에 따라 부신 호르몬 생성을 조절할 수 있는 부신 피질 스테로이드 억제제에 대한 수요가 증가하고 있으며, 유망한 치료 옵션으로 기대를 모으고 있습니다. 또한 코르티코스테로이드의 장기 사용에 따른 부작용에 대한 인식이 높아지면서, 더 안전하고 표적화된 치료법을 위한 연구개발이 촉진되고 있으며, 이는 해당 분야의 시장 성장과 혁신을 더욱 가속화하고 있습니다.
전 세계 코르티코스테로이드 억제제 시장의 제약 요인
전 세계 코르티코스테로이드 억제제 시장에 영향을 미치는 주요 시장 억제요인 중 하나는 의약품 승인 및 시판에 적용되는 엄격한 규제 환경입니다. 승인 절차가 길고 복잡하므로 새로운 치료법의 도입이 지연되어 제약사의 시장 기회가 제한될 수 있습니다. 또한 부신 피질 스테로이드 억제제와 관련된 부작용 위험은 의료 종사자와 환자들 사이에서 우려를 야기하여 신중한 처방 관행으로 이어지고 있습니다. 이러한 경계심 때문에 의사들은 새로운 치료법보다 이미 확립된 치료법을 선호하는 경향이 있으며, 그 결과 임상 현장에서 코르티코스테로이드 억제제의 전반적인 도입에 영향을 미쳐 시장 성장을 제한할 가능성이 있습니다.
전 세계 코르티코스테로이드 억제제 시장 동향
전 세계 코르티코스테로이드 억제제 시장은 치료법 선택을 정교하게 만드는 유전체학의 발전에 힘입어 정밀 의학(Precision Medicine)으로의 큰 전환기를 맞이하고 있습니다. 이러한 진화를 통해 의료 종사자들은 고유한 분자적 특성에 기반하여 특정 환자 하위 집단을 식별할 수 있게 되었으며, 이는 부작용을 최소화하면서 효능을 우선시하는 표적 치료 전략으로 이어지고 있습니다. 그 결과, 제약사들은 제품 개발 과정에 유전체 바이오마커를 통합하는 데 점점 더 주력하고 있으며, 동반 진단 검사를 개발하기 위해 진단 기업과의 제휴를 추진하고 있습니다. 이러한 협력적 접근 방식은 맞춤형 의료 노력을 지원하고, 부신 피질 스테로이드 요법의 전반적인 효능을 높이며, 장기적인 질환 관리에 대한 전 세계적 추세와도 부합합니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 코르티코스테로이드 저해제 시장 규모 : 약제 유형별
세계의 코르티코스테로이드 저해제 시장 규모 : 적응증별
세계의 코르티코스테로이드 저해제 시장 규모 : 유통 채널별
세계의 코르티코스테로이드 저해제 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.09.22Global Adrenal Corticosteroid Inhibitors Market size was valued at USD 782.0 Million in 2024 and is poised to grow from USD 843.0 Million in 2025 to USD 1537.37 Million by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).
The market for global adrenal corticosteroid inhibitors is primarily driven by the increasing incidence of iatrogenic Cushing's disease resulting from prolonged glucocorticoid use, thereby expanding the patient base in need of cortisol-lowering agents. This rising demand has prompted health insurers and providers to adopt approved inhibitors, such as the notable increase in prescriptions following the recent inclusion of osilodrostat in national formularies. Furthermore, the development of combination therapies that incorporate mTOR antagonists is enhancing market opportunities by broadening treatment indications. Additionally, advancements in biosimilar development and digital adherence tools are expected to facilitate market penetration while effectively lowering acquisition costs for health systems. Artificial intelligence is also playing a crucial role by accelerating the discovery of inhibitors, enhancing research efficiency, and fostering collaborations in the biotech sector.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Adrenal Corticosteroid Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Adrenal Corticosteroid Inhibitors Market Segments Analysis
Global adrenal corticosteroid inhibitors market is segmented by drug type, indication, distribution channel and region. Based on drug type, the market is segmented into Steroidogenesis Inhibitors and Glucocorticoid Receptor Antagonists. Based on indication, the market is segmented into Cushing Syndrome, Adrenal Cancer, Hypercortisolism and Other Endocrine Disorders. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Adrenal Corticosteroid Inhibitors Market
A key market driver for the global adrenal corticosteroid inhibitors market is the rising prevalence of autoimmune disorders and inflammatory diseases, which has significantly increased the demand for effective treatment options. As healthcare professionals seek to manage conditions such as rheumatoid arthritis, lupus, and asthma more effectively, the need for adrenal corticosteroid inhibitors that can modulate adrenal hormone production offers promising therapeutic alternatives. Additionally, the growing awareness of the side effects associated with long-term corticosteroid use is propelling research and development efforts toward safer, more targeted therapies, further stimulating market growth and innovation in this sector.
Restraints in the Global Adrenal Corticosteroid Inhibitors Market
One of the key market restraints affecting the global adrenal corticosteroid inhibitors market is the stringent regulatory environment governing the approval and commercialization of pharmaceutical products. The lengthy and complex approval processes can delay the introduction of new therapies, limiting market opportunities for manufacturers. Additionally, the potential for adverse side effects associated with adrenal corticosteroid inhibitors raises concerns among healthcare providers and patients, leading to cautious prescribing practices. This wariness can restrict market growth as doctors may prefer established treatments over newer alternatives, thus impacting the overall adoption of adrenal corticosteroid inhibitors in clinical settings.
Market Trends of the Global Adrenal Corticosteroid Inhibitors Market
The Global Adrenal Corticosteroid Inhibitors market is experiencing a significant shift towards precision medicine, driven by advancements in genomics that refine therapy selection. This evolution allows healthcare providers to identify specific patient subpopulations based on distinct molecular characteristics, leading to targeted treatment strategies that prioritize efficacy while minimizing adverse effects. As a result, pharmaceutical companies are increasingly focused on integrating genomic biomarkers into their product development processes, fostering partnerships with diagnostic firms to create companion tests. This collaborative approach supports personalized medicine initiatives, enhancing the overall effectiveness of adrenal corticosteroid therapies and aligning with global trends in long-term disease management.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Adrenal Corticosteroid Inhibitors Market Size by Drug Type & CAGR (2026-2033)
- Market Overview
- Steroidogenesis Inhibitors
- Glucocorticoid Receptor Antagonists
Global Adrenal Corticosteroid Inhibitors Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Cushing Syndrome
- Adrenal Cancer
- Hypercortisolism
- Other Endocrine Disorders
Global Adrenal Corticosteroid Inhibitors Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Adrenal Corticosteroid Inhibitors Market Size & CAGR (2026-2033)
- North America (Drug Type, Indication, Distribution Channel)
- US
- Canada
- Europe (Drug Type, Indication, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Type, Indication, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Type, Indication, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Type, Indication, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- HRA Pharma Rare Diseases
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Recordati S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Corcept Therapeutics Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amneal Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
